3 Burst results for "Brian Drucker"

"brian drucker" Discussed on News Radio 1190 KEX

News Radio 1190 KEX

01:51 min | 1 year ago

"brian drucker" Discussed on News Radio 1190 KEX

"You're listening to it our top story V. S. Takeda school district is mourning the loss of one of the students who died after being hit by a train while taking a senior photos and Troutdale police say seventeen year old river Baker was posing for photos near the train tracks of the historic Columbia River highway and Graham wrote on Saturday night when the union Pacific train crashed into him he was pronounced dead at the scene the yesterday the school district released a statement on Facebook yesterday saying their thoughts are with Baker's family the mystery of who killed Oregon corrections director Michael Frankie in nineteen eighty nine is now one of the nation's top true crime podcasts eleven ninety K. exes Brad Ford as more it was an assassination Michael Frank he was murdered outside of his office the day before he was to testify about corruption in the department Frank gable was convicted of the killing but a judge recently tossed his conviction because of flaws in the case everyone knows that the state has to know it but they're still hanging on Oregonian columnist Phil Stanford reported on the murder in this part of the podcast murder in Oregon he says by the end of the twelve episode series listers will be able to make their own conclusions about who did it a one hundred million dollar donation to OHSU help to launch the night Cancer Institute that donation came from former Columbia sportswear chairwoman Gert Boyle she died over the weekend that ninety five Dr Brian Drucker who heads the institute tells K. two decades ago he worked with Boyle sister who died from brain cancer when I lost my brother to cancer she sent me a condolence note when I go in visitor and bring your some flowers she'd send me a thank you note and we just became such good friends and and I miss her oils family is asking for donations to be made to the night Cancer Institute the family is working on plans for a celebration of life that was a look at the latest news I'm fills you let newsradio eleven ninety K. E. X. whether.

"brian drucker" Discussed on The Peter Attia Drive

The Peter Attia Drive

03:55 min | 2 years ago

"brian drucker" Discussed on The Peter Attia Drive

"Now, of course, the answers are often not linear per se, but it gives you a route. I mean with come back to the metabolism study that we did Luke Canley that is a great example of taking a non linear problem and converting into a linear problem now to you about that in a second. But any time this was the case with diva to let's tell people what Glivec is. Yeah. Is a good example of a drug where we learned to target a mutant cancer, gene? Gene product. So in that case the cancer. It's a blood cancer called chronic myelogenous. Leukemia was also death sentence and also GI struggle tumor and yesterday to museum chronic myelogenous leukemia was a death sentence. People had to go. Through transplants. I've watched probably dozen in the pre glee Vic era doesn't patients die of chronic myelogenous. Leukemia, the complications of transplant like trained briefly as transplant and then all of a sudden through the work of many people, including Brian Drucker, drug was discovered before that scientists figured out based on very careful genetic analysis that the tumor was being driven by really the work of one, gene. And the gene was called VCR able it's it's an oncogene. It's not found enormous sales, but found in these cancer cells and the product of gene became like a like an engine like a manic engine that was driving these blood cells to go crazy and make more blood cells and proliferating in for the fruit. And it was this engine gone wide inside a cell and every time the sell us the question, should I divide rather than looking at its normal state or nutrients metabolic stated cetera. The only answer would ever get was from his engine saying, yes, go ahead. Make another sale divided cetera et cetera. So this was identified that the exhibit gene product was at the protein product of the gene was identified and then through an elaborate series of experiments in circumstances. Chemists found a way to actually jam the engine a one molecule human beings may we stitch this molecule together it's a remarkable achievement. And once the engine is jammed which suddenly turns out that the disease goes into mission. This was one of the first examples that others of so-called targeted therapy. Will you take you synthesize? A chemical to jam cancers engines in cancer specific way, doesn't affect normal cells. But what's interesting about that is that some people developed resistance because the engine cancer so Volve, and they find a way of resisting. But that was this tits. It becomes a linear problem. You figure out the mechanism the resistance, and you drive a second stake to Kansas heart, and when he becomes into that drive, a third stake and so forth. So all of a sudden the problem would seem like a big blank rock became a linear problem. So that that goes back and other. For example, of how that first stake or the for scramble really helps with the problem. And now immunotherapy MU logical therapy. The roadmap is much clearer. Why do some tumors responded by some don't respond? Visit a question of the environment that the two minutes sitting in is blood vessel is tumor cells immune cells, these are ons Rable questions. These are so called linear questions, but the first big step. Here was to define the problem. This is really a nice step off to exactly where I know. We wanna go, which is we've got surgical oncologists, medical oncologists radiation. Oncologists in many ways, a subset now of medical oncology, immuno based on college the work that you Lou and many others are now doing is potentially nother branch of college called metabolic on college. So you're beyond gracious in. You're suggesting I have even something to do with helping that evening turn into what sounds like a very productive collaboration between you and Lou and I'll be talking with Louis. Well when the next month, I'm sure but. Let's talk a little bit about what came out of that collaboration. And certainly bring it back to Ben Hopkins paper that was a nature. I believe was a NATO weeks ago. Yeah. So let's talk a little bit about the question. What were you trying to understand?.

Leukemia Luke Canley Glivec Lou Ben Hopkins NATO Brian Drucker Kansas Volve Louis two minutes
"brian drucker" Discussed on Novel Targets

Novel Targets

02:25 min | 4 years ago

"brian drucker" Discussed on Novel Targets

"This episode comes from the two thousand and sixteen annual meeting the American society of hematology, commonly known as ash we've called it controversies in hematology because each of the expert show here officer, very personal view. The not everyone is going to agree with leading them fomer specialist tells us what he really thinks about Carty. So I I'm not ready to go to my desert island with only a cartesian L agent to treat whatever patient, I might encounter and have the right targets being chosen for pioneering trial in acute myeloid leukemia. AM, oh, you're over sixty the survival rates. No more than about two percent at ten years. We have to do something better in ceelo, chronic lymphocytic. Leukemia will hear what it liberal expert for it was exciting at the me too. So it's sort of tastes great less filling version of brew. Linden. Now is it really better in his own little trial. It seems to be better. Finally, one of the prominent topics at fishes ash meeting was sickle cell disease, while we're excited about novel therapies, a lot of ad is actually controlling the disease, but what about cure? We'll hear more about the potential for gene editing and gene therapy later immature. This so despondent punch and Intech over the past two years. They sponsored fifteen episodes would grateful for their support and just to be clear if we do mention any products we made an independent Detroit decision to do. So our sponsors have no control of the topics. We cover who we interview of questions we asked. So let's start with a mentioned for the leukemia and lymphoma society at Ashby out to major new initiative called beat AML, this postering and adaptive clinical trial that will investigate multiple targets with multiple drugs from different companies. This approach has never been done before AML. Will it be a game changer? I spoke to one of lead investigators. I'm Brian Drucker director of the Oregon Health and science university night, Ken through toot in Portland, Oregon beat AML really is groundbreaking. We're going to be able to assign patients over sixty two treatment based on their genetic makeup of leukemia within seven days of diagnosis and our goals to try to have a treatment for every single patient who enrolls, and that's truly remarkable.

Leukemia AML American society of hematology Carty Oregon Health and science univ Intech officer Oregon Brian Drucker Linden Ashby cure Detroit Ken director Portland two percent seven days ten years two years